SEPTIN9 and colorectal carcinoma: SEPT9 combined with ALX4 and HPP1 was tested in plasma from 182 CRC cases (stage I-III) and 170 healthy controls and yielded a sensitivity of 80.7% at a specificity of 90% [112].